Chronic myelogenous leukemia: Mechanisms underlying disease progression

Leukemia

Volumn 16, Issue 8, 2002, Pages 1402-1411

  Shet, A S ^a   Jahagirdar, B N ^a   Verfaillie, C M ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

BCR ABL; Blast crisis; Chronic myelogenous leukemia; Disease progression; Mechanisms

Indexed keywords

BCR ABL PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; BLAST CELL CRISIS; CANCER INHIBITION; CARCINOGENESIS; CHRONIC MYELOID LEUKEMIA; CLINICAL FEATURE; CONTROLLED STUDY; CYTOGENETICS; DISEASE ASSOCIATION; DISEASE COURSE; GENE REARRANGEMENT; HUMAN; IMMUNOSURVEILLANCE; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; REVIEW; TUMOR SUPPRESSOR GENE;

EID: 0036050013     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402577     Document Type: Review

References (174)

1. Clinical features at diagnosis in 430 patients with chronic myeloid leukaemia seen at a referral centre over a 16-year period
2. The clinical features of chronic granulocytic leukaemia
3. Chronic myelogenous leukemia in blast crisis. Analysis of 242 patients
4. Definition of the accelerated phase of chronic myelogenous leukemia
5. Related donor bone marrow transplantation for chronic myelogenous leukemia
6. An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: Developed for the American Society of Hematology
7. Unrelated donor marrow transplantation for chronic myelogenous leukemia: 9 years' experience of the national marrow donor program
8. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. The Leukemia Service
9. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products
10. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome
11. bcr-abl, the hallmark of chronic myeloid leukaemia in man, induces multiple haemopoietic neoplasms in mice
12. Acute leukaemia in bcr/abl transgenic mice
13. Efficient transplantation of BCR-ABL-induced chronic myelogenous leukemia-like syndrome in mice
14. In vitro transformation of immature hematopoietic cells by the P210 BCR/ABL oncogene product of the Philadelphia chromosome
15. Initiation of deregulated growth of multipotent progenitor cells by bcr-abl in vitro
16. A minute chromosome in human chronic granulocytic leukemia
17. Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining
18. The BCR/ABL hybrid gene
19. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products
20. The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene
21. An actin-binding function contributes to transformation by the Bcr-Abl oncoprotein of Philadelphia chromosome-positive human leukemias
22. Expression of bcr-abl abrogates factor-dependent growth of human hematopoietic M07E cells by an autocrine mechanism
23. Development of acute lymphoblastic leukemia and myeloproliferative disorder in transgenic mice expressing p210bcr/abl: A novel transgenic model for human Ph1-positive leukemias
24. Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow
25. Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL
26. BCR/ABL P210 and P190 cause distinct leukemia in transgenic mice
27. The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity
28. Abl tyrosine protein kinase
29. Abl tyrosine kinase in signal transduction and cell-cycle regulation
30. Dominant negative MYC blocks transformation by ABL oncogenes
31. Biochemical and genetic control of apoptosis: Relevance to normal hematopoiesis and hematological malignancies
32. The cytostatic function of c-Abl is controlled by multiple nuclear localization signals and requires the p53 and Rb tumor suppressor gene products
33. Interaction of c-Abl and p73alpha and their collaboration to induce apoptosis
34. Ataxia telangiectasia mutant protein activates c-Abl tyrosine kinase in response to ionizing radiation
35. Functional role for the c-Abl protein tyrosine kinase in the cellular response to genotoxic stress
36. Regulation of cell death by the abl tyrosine kinase
37. Integrins regulate the association and phosphorylation of paxillin by c- Abl
38. The c-Abl tyrosine kinase is regulated downstream of the B cell antigen receptor and interacts with CD19
39. Neonatal lethality and lymphopenia in mice with a homozygous disruption of the c-abl proto-oncogene
40. Increased neutrophil respiratory burst in bcr-null mutants
41. Biology of chronic myelogenous leukemia
42. Molecular consequences of the BCR-ABL translocation in chronic myelogenous leukemia
43. The biology of chronic myeloid leukemia
44. Chronic myeloid leukemia from basics to bedside
45. A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins
46. BCR first exon sequences specifically activate the BCR/ABL tyrosine kinase oncogene of Philadelphia chromosome-positive human leukemias
47. SH1 domain autophosphorylation of P210 BCR/ABL is required for transformation but not growth factor independence
48. Bcr phosphorylated on tyrosine 177 binds Grb2
49. Genetic requirement for Ras in the transformation of fibroblasts and hematopoietic cells by the Bcr-Abl oncogene
50. Coupling between p210bcr-abl and Shc and Grb2 adaptor proteins in hematopoietic cells permits growth factor receptor-independent link to ras activation pathway
51. Association of the protein kinases c-Bcr and Bcr-Abl with proteins of the 14-3-3 family
52. Association of Sos Ras exchange protein with Grb2 is implicated in tyrosine kinase signal transduction and transformation
53. Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia
54. P210 and P190(BCR/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members
55. Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl
56. BCR/abl leads to the constitutive activation of Stat proteins, and shares an epitope with tyrosine phosphorylated Stats
57. p62(dok): A constitutively tyrosine-phosphorylated, GAP-associated protein in chronic myelogenous leukemia progenitor cells
58. Tyrosine phosphorylation of p120cbl in BCR/abl transformed hematopoietic cells mediates enhanced association with phosphatidylinositol 3-kinase
59. Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells
60. PI3K: Downstream AKT ion blocks apoptosis
61. Tumorigenic activity of the BCR-ABL oncogenes is mediated by BCL2
62. STAT5-dependent cyclinD1 and Bcl-xL expression in Bcr-Abl-transformed cells
63. Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-xL
64. The COOH terminus of the c-Abl tyrosine kinase contains distinct F- and G-actin binding domains with bundling activity
65. BCR/ABL induces multiple abnormalities of cytoskeletal function
66. Tyrosine phosphorylation and activation of focal adhesion kinase (p125FAK) by BCR-ABL oncoprotein
67. Molecular cloning of human paxillin, a focal adhesion protein phosphorylated by P210BCR/ABL
68. Altered adhesive interactions with marrow stroma of haematopoietic progenitor cells in chronic myeloid leukaemia
69. Inhibition of BCR-ABL expression with antisense oligodeoxynucleotides restores beta1 integrin-mediated adhesion and proliferation inhibition in chronic myelogenous leukemia hematopoietic progenitors
70. The Bcr-Abl tyrosine kinase activates mitogenic signaling pathways and stimulates G1-to-S phase transition in hematopoietic cells
71. Association of phosphatidylinositol 3-kinase with SHC in chronic myelogeneous leukemia cells
72. BCL-2 gene family and the regulation of programmed cell death
73. Bcr/Abl activates transcription of the Bcl-X gene through STAT5
74. BCR-ABL-mediated inhibition of apoptosis with delay of G2/M transition after DNA damage: A mechanism of resistance to multiple anticancer agents
75. Structural and signaling requirements for BCR-ABL-mediated transformation and inhibition of apoptosis
76. ts BCR-ABL kinase activation confers increased resistance to genotoxic damage via cell cycle block
77. Primary proliferating immature myeloid cells from CML patients are not resistant to induction of apoptosis by DNA damage and growth factor withdrawal
78. Apoptosis in chronic myeloid leukaemia: Normal responses by progenitor cells to growth factor deprivation, X-irradiation and glucocorticoids
79. BCR-ABL: An anti-apoptosis gene in chronic myelogenous leukemia
80. Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia
81. BCR-ABL maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death
82. Bcr-Abl exerts its antiapoptotic effect against diverse apoptotic stimuli through blockage of mitochondrial release of cytochrome C and activation of caspase-3
83. BCR-ABL delays apoptosis upstream of procaspase-3 activation
84. A requirement for NF-kappaB activation in Bcr-Abl-mediated transformation
85. Regulation of Bcl-2 gene expression by BCR-ABL is mediated by Ras
86. The BCR-ABL tyrosine kinase inhibits apoptosis by activating a Ras-dependent signaling pathway
87. Suppression of apoptotic death in hematopoietic cells by signalling through the IL-3/GM-CSF receptors
88. Apoptosis in chronic myelogenous leukemia: Studies of stage-specific differences
89. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia
90. Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase
91. BCR-ABL activates pathways mediating cytokine independence and protection against apoptosis in murine hematopoietic cells in a dose-dependent manner
92. Increase of bcr-abl chimeric mRNA expression in tumor cells of patients with chronic myeloid leukemia precedes disease progression
93. Subcellular localization of Bcr, Abl, and Bcr-Abl proteins in normal and leukemic cells and correlation of expression with myeloid differentiation
94. CML: Mechanisms of disease initiation and progression
95. Cell biology of CML cells
96. The control of hematopoiesis and leukemia: From basic biology to the clinic
97. Effect of differentiation-inducing agents on oncogene expression in a chronic myelogenous leukemia cell line
98. Chronic myeloid leukemia as an immunological target
99. The role of FAS-mediated apoptosis in chronic myelogenous leukemia
100. Fas ligand is highly expressed in acute leukemia and during the transformation of chronic myeloid leukemia to blast crisis
101. The role of autologous natural killer cells in chronic myelogenous leukemia
102. CD56+bright and CD56+dim natural killer cells in patients with chronic myelogenous leukemia progressively decrease in number, respond less to stimuli that recruit clonogenic natural killer cells, and exhibit on a per cell basis
103. Sensitivity to the abl inhibitor STI571 in fresh leukaemic cells obtained from chronic myelogenous leukaemia patients in different stages of disease
104. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: Diverse mechanisms of resistance
105. Studies of some mechanisms of drug resistance in chronic myeloid leukemia (CML)
106. Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571
107. Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines
108. The cytogenetic scenario of chronic myeloid leukemia
109. Karyotype abnormalities and their clinical significance in blast crisis of chronic myeloid leukemia
110. Alterations in the p53 gene and the clonal evolution of the blast crisis of chronic myelocytic leukemia
111. p53 loss and point mutations are associated with suppression of apoptosis and progression of CML into myeloid blastic crisis
112. Rearrangement and expression of p53 in the chronic phase and blast crisis of chronic myelogenous leukemia
113. Homozygous deletions of the p16 tumor-suppressor gene are associated with lymphoid transformation of chronic myeloid leukemia
114. Abnormalities of the retinoblastoma gene in the pathogenesis of acute leukemia
115. Detection of c-myc oncogene amplification in a CML blastic phase patient with double minute chromosomes
116. Abnormal regulation of the myc gene in myeloid leukemia
117. Studies of proto-oncogene expression in the chronic and blastic phases of chronic myelogenous leukemia
118. The changes of mRNAs of both c-myc and MDR1 in CML-bc tumor cells during the clinical course: A case report
119. Transforming genes in chronic myelogenous leukemia
120. Generation of the AML1-EVI-1 fusion gene in the t(3;21)(q26;q22) causes blastic crisis in chronic myelocytic leukemia
121. Karyotypic changes during the course of blastic crisis of chronic myelogenous leukemia
122. Responses to DNA damage and regulation of cell cycle checkpoints by the ATM protein kinase family
123. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene
124. Cell surface trafficking of Fas: A rapid mechanism of p53-mediated apoptosis
125. Induction of the TRAIL receptor KILLER/DR5 in p53-dependent apoptosis but not growth arrest
126. p53, the cellular gatekeeper for growth and division
127. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
128. Role of p53 in leukemogenesis of chronic myeloid leukemia
129. A splicing mutation accounts for the lack of p53 gene expression in a CML blast crisis cell line: A novel mechanism of p53 gene inactivation
130. Isochromosome 17q in blast crisis of chronic myeloid leukemia and in other hematologic malignancies is the result of clustered breakpoints in 17p11 and is not associated with coding TP53 mutations
131. The spectrum of molecular alterations in the evolution of chronic myelocytic leukemia
132. Blast crisis of Ph-positive chronic myeloid leukemia with isochromosome 17q: Report of 12 cases and review of the literature
133. Retroviral transduction of Philadelphia-positive chronic myeloid leukemia cells with a human mutant p53 cDNA and its effect on in vitro proliferation
134. Acquired loss of p53 induces blastic transformation in p210(bcr/abl)-expressing hematopoietic cells: A transgenic study for blast crisis of human CML
135. Blastic transformation of p53-deficient bone marrow cells by p210bcr/abl tyrosine kinase
136. Correlation between molecular and clinical events in the evolution of chronic myelocytic leukemia to blast crisis
137. Biphenotypic blast crisis of chronic myelogenous leukemia: Abnormalities of p53 and retinoblastoma genes
138. Involvement of the cyclin-dependent kinase-4 inhibitor (CDKN2) gene in the pathogenesis of lymphoid blast crisis of chronic myelogenous leukaemia
139. p16ink4a gene and hematological malignancies
140. Review of alterations of the cyclin-dependent kinase inhibitor INK4 family genes p15, p16, p18 and p19 in human leukemia-lymphoma cells
141. ABL1 methylation is a distinct molecular event associated with clonal evolution of chronic myeloid leukemia
142. Molecular follow-up of disease progression and interferon therapy in chronic myelocytic leukemia
143. Methylation of the ABL1 promoter in chronic myelogenous leukemia: Lack of prognostic significance
144. Progressive de novo DNA methylation at the bcr-abl locus in the course of chronic myelogenous leukemia
145. Acceleration of chronic myeloid leukemia correlates with calcitonin gene hypermethylation
146. Frequent and extensive deletion during the 9,22 translocation in CML
147. Analysis of breakpoints within the bcr gene and their correlation with the clinical course of Philadelphia-positive chronic myelogenous leukemia
148. Large deletions at the t(9;22) breakpoint are common and may identify a poor-prognosis subgroup of patients with chronic myeloid leukemia
149. Decreases in Ikaros activity correlate with blast crisis in patients with chronic myelogenous leukemia
150. Loss of imprinting in disease progression in chronic myelogenous leukemia
151. Significance of cytogenetic clonal evolution in chronic myelogenous leukemia
152. Differential complementation of Bcr-Abl point mutants with c-Myc
153. Antileukemia effect of c-myc N3′-→P5′ phosphoramidate antisense oligonucleotides in vivo
154. Antisense oligodeoxynucleotide combination therapy of primary chronic myelogenous leukemia blast crisis in SCID mice
155. Bcl-2 and c-myc expression, cell cycle kinetics and apoptosis during the progression of chronic myelogenous leukemia from diagnosis to blastic phase
156. Identification of several genes differentially expressed during progression of chronic myelogenous leukemia
157. c-Myc antagonizes the effect of p53 on apoptosis and p21WAF1 transactivation in K562 leukemia cells
158. Molecular characteristics of chronic myelogenous leukemia in blast crisis
159. Structurally altered Evi-1 protein generated in the 3q21q26 syndrome
160. Increased Evi-1 expression is frequently observed in blastic crisis of chronic myelocytic leukemia
161. EVI1 expression associated with a 3q26 anomaly in a leukemia cell line derived from the blast crisis of chronic myeloid leukemia
162. Molecular mechanism of blastic crisis in chronic myelocytic leukemia
163. Alternative signals to RAS for hematopoietic transformation by the BCR-ABL oncogene
164. Role of p21 RAS in p210 bcr-abl transformation of murine myeloid cells
165. Bcr-Abl oncoproteins bind directly to activators of the Ras signalling pathway
166. Ras oncogene mutations are rare late stage events in chronic myelogenous leukemia
167. Absence of N-ras mutations in myeloid and lymphoid blast crisis of chronic myeloid leukemia
168. Absence of microsatellite instability during the progression of chronic myelocytic leukemia
169. Genomic instability of microsatellite repeats and its association with the evolution of chronic myelogenous leukemia
170. p53 mutations, methylation and genomic instability in the progression of chronic myeloid leukaemia
171. The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage
172. BCR-ABL down-regulates the DNA repair protein DNA-PKcs
173. Catalogue of Chromosomal Aberrations
174. The Bcr-Abl leukemia oncogene activates Jun kinase and requires Jun for transformation